July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
In vitro study with delta-9-tetrahydrocannabinol (THC) solution to decrease intraocular pressure and neuroprotection
Author Affiliations & Notes
  • Marisa Arcos
    opthalmology, Universidad del Salvador, Buenos aires, Argentina
    Research Department, Universidad Catolica de Cuenca, Cuenca, Azuay, Ecuador
  • Veronica Matovelle
    Universidad Catolica de Cuenca, Cuenca, Ecuador
  • hugo llerena
    Universidad Catolica de Cuenca, Cuenca, Ecuador
  • Nervo Sanchez
    Consultor Independiente, Cuenca, Ecuador
  • Jorge Tintin
    Universidad Catolica de Cuenca, Cuenca, Ecuador
  • Helen Toapanta
    Universidad Catolica de Cuenca, Cuenca, Ecuador
  • Footnotes
    Commercial Relationships   Marisa Arcos, None; Veronica Matovelle, None; hugo llerena, None; Nervo Sanchez, None; Jorge Tintin, None; Helen Toapanta, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1238. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marisa Arcos, Veronica Matovelle, hugo llerena, Nervo Sanchez, Jorge Tintin, Helen Toapanta; In vitro study with delta-9-tetrahydrocannabinol (THC) solution to decrease intraocular pressure and neuroprotection. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1238.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Introduction: recent research shows that Cannabis may not only treat glaucoma by reducing eye pressure, but it may also act on certain receptors to provide a type of neuro-protection against damage to the optic nerve. Scientists have conducted studies in which patients ingested THC through oral (by mouth) or sublingual (under the tongue) methods and in topical eye drops. Eye drops TCH sounds like the most logical method of taking the drug. But TCH is not very water soluble, so it has been difficult to develop an eye drop with high enough concentrations of TCH to be effective.
Objetive: To research different concentrations of TCH using glycerol solvent in hidroxipropilmetilcelulose a typical eye drop component.

Methods : Materials and Methods: Cannabis Sativa, 12gr, glycerol 150ml, hidroxipropilmetilcelulose 45ml (3mg/ml) from two samples A=3gr, and B=8gr. Descarboxilation at 120°C to eliminate TCH acid forms, we used glycerol as solvent macerate TCH shking during a day, strained by vacuum pump. Finally, we mixed the previous solution whit hidroxipropilmetilcelulose (3mg/ml) using liquid chromatography to check TCH concentrations.

Results : Results: Cromatography shows sample A TCH 305mg/ml and B TCH 607mg/ml. The solution of 1ml of each sample in 15 ml of hidroxipropilmetilcelulose (3mg/ml) result in A. 20.3mg/ml (1.01mg/drop) B 40.4 mg/ml (2.02 mg/drop)

Conclusions : Conclusions: It was demonstrated in previous studies that some cannabinoid agonists act as «ideal drugs» in the management of glaucoma, as they have been shown to have good tolerability after topical application, efficiently reduce intraocular pressure, and behave as neuroprotectors on retinal ganglion cells.
The availability of TCH in hidroxipropilmetilcelulose was high.
Further studies as regards the safety and clinical assays must be carried out in order to examine the effectiveness of these drugs for the treatment of glaucoma in our daily clinical practice.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.